Pipeline Overview

SARKKOS Therapeutics is advancing a small-molecule discovery program that progresses to the hit discovery phase for our specific target. Our research focuses on a target (a cell receptor) that is potentially implicated as a driver linking obesity to the development and progression of solid tumours. 

Obesity creates a pro-tumorigenic microenvironment, which modulates tumour cell proliferation and potentially modulates immune evasion in obese tumour microenvironments. By having a clear understanding of the mechanism of action of our target and developing drugable small-molecule inhibitors against it, we will address its potential critical role in obesity-related solid cancer.

SARKKOS Therapeutics aims to identify promising leads using high-throughput and computational screening. Those leads will be confirmed against validated disease models. Our pipeline initially focuses on several obesity-related solid cancers and plans to expand into other cancers in the future.